Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has stated that it would be presenting at the 13th Annual ENETS Conference, due to be held in Barcelona, Spain, from March 9 to 11, 2016. The conference is focused on the treatment of neuroendocrine tumors. Lexicon has been asked to present data from a study of the open label extension of Telestar. The study is currently in the phase-3 of clinical trials.
The company’s abstract from the study has been classified under “Session 8” of the conference, titled: “What’s New in the Field?” The presentation has been titled “Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome not Adequately Controlled by Somatostatin Analog Therapy”. Furthermore, Dieter Hörsch would deliver the presentation.
Although the presentation is to be held on March 11, Lexicon will also display a poster from March 10. The poster focuses on patients interviewed during the phase-3 study of Telestar. The presenter for the poster is going to be Marianne Pavel, a Senior Physician in Berlin, Germany. Prior to the ENETS conference, the company had released the results at the European Cancer conference and the symposium of the North-American Neuroendocrine Tumore Society.
Furthermore, Lexicon will also update on the clinical development programs and milestones of the company, during the Cowen and Company 36th Annual Healthcare Conference. Recently, the company had announced its 4Q2015 and FY2015 results, reporting a profit of $86.8 million, in the 4Q2015. Lexicon had reported a loss, during the same period, in the preceding year and also beat analyst estimates of $0.38 per share, compared to the actual EPS of $0.76.
However, for the FY2015, the company still reported a loss of 5-cents per share, but the figure was much narrower than expected. During the earnings call, the management announced that it would continue to focus on its orphan drug, telotristat etiprate, used for the treatment of carcinoid syndrome and sotagliflozin, the drug for diabetes.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) experienced a decline of 6.15% and closed at a share price of $10.99, at the end of the March 8 trading session.
